Telomerase inhibition decreases alpha-fetoprotein expression and secretion by hepatocellular carcinoma cell lines: In vitro and in vivo study

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Tahtouh, Roula ^a   Azzi, Anne Sophie ^a   Alaaeddine, Nada ^a   Chamat, Soulaima ^b   Bouharoun Tayoun, Hasnaa ^b   Wardi, Layal ^a   Raad, Issam ^c   Sarkis, Riad ^d   Antoun, Najibe Abou ^b   Hilal, George ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b LEBANESE UNIVERSITY   (Lebanon)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; SMALL INTERFERING RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; AFP PROTEIN, HUMAN; AMINOBENZOIC ACID DERIVATIVE; BIBR 1532; COSTUNOLIDE; ENZYME INHIBITOR; MTOR PROTEIN, HUMAN; NAPHTHALENE DERIVATIVE; RNA; SESQUITERPENE; TARGET OF RAPAMYCIN KINASE; TERT PROTEIN, HUMAN;

ALPHA FETOPROTEIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PLC CELL LINE; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEP-G2 CELL LINE; LIVER NEOPLASMS; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PREVENTION AND CONTROL; SCID MOUSE; TUMOR CELL LINE; TUMOR INVASION;

MUS;

ALPHA-FETOPROTEINS; AMINOBENZOATES; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME INHIBITORS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NAPHTHALENES; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; SESQUITERPENES; SIGNAL TRANSDUCTION; TELOMERASE; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926382695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119512     Document Type: Article

References (85)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132: 2557-2576. doi: 10.1053/j.gastro.2007.04.061 PMID: 17570226
2. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011; 140: 1182-1188.e1. doi: 10.1053/j.gastro.2010.12.032 PMID: 21184757
3. Petta S, Craxì A. Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. Curr Pharm Des. 2010; 16: 741-752. PMID: 20388084
4. Page JM, Harrison SA. NASH and HCC. Clin Liver Dis. 2009; 13: 631-647. doi: 10.1016/j.cld.2009.07.007 PMID: 19818310
5. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004; 126: 460-468. PMID: 14762783
6. Torzilli G, Belghiti J, Makuuchi M. Differences and similarities in the approach to hepatocellular carcinoma between Eastern and Western institutions. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2004; 10: S1-2. doi: 10.1002/lt.20032
7. Diamandis EP, Fritsch HA, Chan DW, Schwartz MK. Tumor markers in primary malignancies. cahpter 22, page 269-279: AACC Press; 2002.
8. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med Maywood NJ. 2001; 226: 377-408. PMID: 11393167
9. Gitlin D, Perricelli A, Gitlin GM. Synthesis of-fetoprotein by liver, yolk sac, and gastrointestinal tract of the human conceptus. Cancer Res. 1972; 32: 979-982. PMID: 4111729
10. Mizejewski GJ. Levels of alpha-fetoprotein during pregnancy and early infancy in normal and disease states. Obstet Gynecol Surv. 2003; 58: 804-826. doi: 10.1097/01.OGX.0000099770.97668.18 PMID: 14668662
11. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet. 1984; 1: 926-929. PMID: 6201687
12. Beaman JM, Goldie DJ. Second trimester screening for Down's syndrome: 7 years experience. J Med Screen. 2001; 8: 128-131. PMID: 11678551
13. Gregory JJ Jr, Finlay JL. Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers. Drugs. 1999; 57: 463-467. PMID: 10235686
14. Lee YS, Choe GY, Hong SI, Lee MJ, Kim TH, Jang JJ. Changes in natural killer cell activity and prostaglandin E2 levels during the progression of diethylnitrosamine-induced hepatocarcinogenesis in Fischer 344 rats. Oncol Rep. 1998; 5: 1441-1445. PMID: 9769384
15. Hu K-Q, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol. 2004; 99: 860-865. doi: 10.1111/j.1572-0241.2004.04152.x PMID: 15128351
16. Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol. 1998; 93: 2452-2456. doi: 10.1111/j.1572-0241.1998.00703.x PMID: 9860408
17. Christiansen M, Høgdall CK, Andersen JR, Nørgaard-Pedersen B. Alpha-fetoprotein in plasma and serum of healthy adults: preanalytical, analytical and biological sources of variation and construction of age-dependent reference intervals. Scand J Clin Lab Invest. 2001; 61: 205-215. PMID: 11386607
18. Mizejewski GJ. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther. 2002; 2: 709-735. doi: 10.1586/14737140.2.6.709 PMID: 12503217
19. Mizejewski GJ. Biological roles of alpha-fetoprotein during pregnancy and perinatal development. Exp Biol Med Maywood NJ. 2004; 229: 439-463. PMID: 15169963
20. Galarneau L, Paré JF, Allard D, Hamel D, Levesque L, Tugwood JD, et al. The alpha1-fetoprotein locus is activated by a nuclear receptor of the Drosophila FTZ-F1 family. Mol Cell Biol. 1996; 16: 3853-3865. PMID: 8668203
21. Wen P, Locker J. A novel hepatocytic transcription factor that binds the alpha-fetoprotein promoter-linked coupling element. Mol Cell Biol. 1994; 14: 6616-6626. PMID: 7523856
22. Guertin M, LaRue H, Bernier D, Wrange O, Chevrette M, Gingras MC, et al. Enhancer and promoter elements directing activation and glucocorticoid repression of the alpha 1-fetoprotein gene in hepatocytes. Mol Cell Biol. 1988; 8: 1398-1407. PMID: 2454390
23. Bois-Joyeux B, Danan JL. Members of the CAAT/enhancer-binding protein, hepatocyte nuclear factor- 1 and nuclear factor-1 families can differentially modulate the activities of the rat alpha-fetoprotein promoter and enhancer. Biochem J. 1994; 301 (Pt 1): 49-55.
24. Feuerman MH, Godbout R, Ingram RS, Tilghman SM. Tissue-specific transcription of the mouse alphafetoprotein gene promoter is dependent on HNF-1. Mol Cell Biol. 1989; 9: 4204-4212. PMID: 2479822
25. Apergis GA, Crawford N, Ghosh D, Steppan CM, Vorachek WR, Wen P, et al. A novel nk-2-related transcription factor associated with human fetal liver and hepatocellular carcinoma. J Biol Chem. 1998; 273: 2917-2925. PMID: 9446603
26. Li C, Locker J, Wan YJ. RXR-mediated regulation of the alpha-fetoprotein gene through an upstream element. DNA Cell Biol. 1996; 15: 955-963. PMID: 8945636
27. Magee TR, Cai Y, El-Houseini ME, Locker J, Wan YJ. Retinoic acid mediates down-regulation of the alpha-fetoprotein gene through decreased expression of hepatocyte nuclear factors. J Biol Chem. 1998; 273: 30024-30032. PMID: 9792724
28. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997; 90: 595-606. PMID: 9288740
29. Olsson M, Lindahl G, Ruoslahti E. Genetic control of alpha-fetoprotein synthesis in the mouse. J Exp Med. 1977; 145: 819-827. PMID: 67170
30. Belayew A, Tilghman SM. Genetic analysis of alpha-fetoprotein synthesis in mice. Mol Cell Biol. 1982; 2: 1427-1435. PMID: 6186903
31. Semenkova L, Dudich E, Dudich I, Tokhtamisheva N, Tatulov E, Okruzhnov Y, et al. Alpha-fetoprotein positively regulates cytochrome c-mediated caspase activation and apoptosome complex formation. Eur J Biochem FEBS. 2003; 270: 4388-4399. PMID: 14622304
32. Alava MA, Iturralde M, Lampreave F, Piñeiro A. Specific uptake of alpha-fetoprotein and albumin by rat Morris 7777 hepatoma cells. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 1999; 20: 52-64.
33. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004; 30: 193-204. doi: 10.1016/j.ctrv.2003.07.007 PMID: 15023437
34. Wang B, Xiao Z, Chen B, Han J, Gao Y, Zhang J, et al. Nogo-66 promotes the differentiation of neural progenitors into astroglial lineage cells through mTOR-STAT3 pathway. PloS One. 2008; 3: e1856. doi: 10.1371/journal.pone.0001856 PMID: 18365011
35. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci. 2009; 1171: 59-76. doi: 10.1111/j.1749-6632.2009.04911.x PMID: 19723038
36. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB. 2005; 7: 26-34. doi: 10.1080/13651820410024049 PMID: 18333158
37. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol Off J Am Soc Clin Oncol. 2009; 27: 5734-5742. doi: 10.1200/JCO.2009.23.1282
38. Buseman CM, Wright WE, Shay JW. Is telomerase a viable target in cancer? Mutat Res. 2012; 730: 90-97. doi: 10.1016/j.mrfmmm.2011.07.006 PMID: 21802433
39. Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev. 1995; 5: 249-255. PMID: 7613096
40. Greider CW. Telomere length regulation. Annu Rev Biochem. 1996; 65: 337-365. doi: 10.1146/ annurev.bi.65.070196.002005 PMID: 8811183
41. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis. 2005; 26: 867-874. doi: 10.1093/carcin/bgh296 PMID: 15471900
42. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997; 277: 955-959. PMID: 9252327
43. Mehdipour Parvin. Telomere Territory and Cancer. Springer; 2012.
44. Gavory G, Balasubramanian S. PNA and Oligonucleotide Inhibitors of Human Telomerase [Internet]. 2000 [cited 17 Jan 2014]. Available: http://www.ncbi.nlm.nih.gov/books/NBK6469/
45. Harrington L. Biochemical aspects of telomerase function. Cancer Lett. 2003; 194: 139-154. PMID: 12757972
46. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997; 90: 785-795. PMID: 9288757
47. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A. 1995; 92: 9082-9086. PMID: 7568077
48. Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 1998; 16: 1217-1222. doi: 10.1038/sj.onc.1201882 PMID: 9528864
49. Akiyama M, Iwase S, Horiguchi-Yamada J, Saito S, Furukawa Y, Yamada O, et al. Interferon-alpha repressed telomerase along with G1-accumulation of Daudi cells. Cancer Lett. 1999; 142: 23-30. PMID: 10424777
50. Terasaki M, Kato S, Sugita Y, Shigemori M, Morimatsu M. Adenovirus-mediated over-expression of p21Waf-1 differentially affects the proliferation, telomerase activity, and expression of glial fibrillary acidic protein in human glioma cells. Int J Oncol. 1999; 14: 63-69. PMID: 9863010
51. Dessain SK, Yu H, Reddel RR, Beijersbergen RL, Weinberg RA. Methylation of the human telomerase gene CpG island. Cancer Res. 2000; 60: 537-541. PMID: 10676632
52. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, et al. Direct activation of TERT transcription by c-MYC. Nat Genet. 1999; 21: 220-224. doi: 10.1038/6010 PMID: 9988278
53. Xiao X, Phogat SK, Sidorov IA, Yang J, Horikawa I, Prieto D, et al. Identification and characterization of rapidly dividing U937 clones with differential telomerase activity and gene expression profiles: role of c- Myc/Mad1 and Id/Ets proteins. Leukemia. 2002; 16: 1877-1880. doi: 10.1038/sj.leu.2402607 PMID: 12200713
54. Akiyama M, Hideshima T, Hayashi T, Tai Y-T, Mitsiades CS, Mitsiades N, et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002; 62: 3876-3882. PMID: 12097303
55. Kumar M, Witt B, Knippschild U, Koch S, Meena JK, Heinlein C, et al. CEBP factors regulate telomerase reverse transcriptase promoter activity in whey acidic protein-T mice during mammary carcinogenesis. Int J Cancer J Int Cancer. 2013; 132: 2032-2043. doi: 10.1002/ijc.27880 PMID: 23023397
56. Li H, Zhao LL, Funder JW, Liu JP. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J Biol Chem. 1997; 272: 16729-16732. PMID: 9201974
57. Ghous Z, Akhter J, Pourgholami MH, Morris DL. Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study. Anticancer Res. 2008; 28: 3757-3761. PMID: 19189661
58. Chan SL, Mo FKF, Johnson PJ, Hui EP, Ma BBY, Ho WM, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2009; 27: 446-452. doi: 10.1200/JCO.2008.18.8151
59. Chen L-T, Shiah H-S, Chao Y, Chang J-Y, Cheng L-T, Whang-Peng J. Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent. J Clin Oncol Off J Am Soc Clin Oncol. 2009; 27: e271; author reply e272. doi: 10.1200/JCO.2009.23.8311
60. Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. The oncologist. 2009; 14: 717-725. doi: 10.1634/theoncologist.2009-0038 PMID: 19581525
61. Alpert E. serum alpha-fetoprotein in hepatoma patients after liver transplantation. 1971.
62. Kondo F, Wada K, Nagato Y, Nakajima T, Kondo Y, Hirooka N, et al. Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria. Hepatol Baltim Md. 1989; 9: 751-755.
63. Miura N, Shiota G, Nakagawa T, Maeda Y, Sano A, Marumoto A, et al. Sensitive detection of human telomerase reverse transcriptase mRNA in the serum of patients with hepatocellular carcinoma. Oncology. 2003; 64: 430-434. doi: 70303 PMID: 12759542
64. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390. doi: 10.1056/NEJMoa0708857 PMID: 18650514
65. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, dou-ble- blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34. doi: 10.1016/S1470-2045(08)70285-7 PMID: 19095497
66. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003; 23: 1747-1753. PMID: 12820452
67. Qu Y, Mao M, Li X, Zhang L, Huang X, Yang C, et al. Enhanced migration and CXCR4 over-expression in fibroblasts with telomerase reconstitution. Mol Cell Biochem. 2008; 313: 45-52. doi: 10.1007/s11010-008-9740-6 PMID: 18363039
68. Sato N, Maehara N, Mizumoto K, Nagai E, Yasoshima T, Hirata K, et al. Telomerase activity of cultured human pancreatic carcinoma cell lines correlates with their potential for migration and invasion. Cancer. 2001; 91: 496-504. PMID: 11169932
69. Vo BT, Morton D Jr, Komaragiri S, Millena AC, Leath C, Khan SA. TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology. 2013; 154: 1768-1779. doi: 10.1210/en.2012-2074 PMID: 23515290
70. Etienne-Manneville S. Polarity proteins in migration and invasion. Oncogene. 2008; 27: 6970-6980. doi: 10.1038/onc.2008.347 PMID: 19029938
71. Merlot S, Firtel RA. Leading the way: Directional sensing through phosphatidylinositol 3-kinase and other signaling pathways. J Cell Sci. 2003; 116: 3471-3478. doi: 10.1242/jcs.00703 PMID: 12893811
72. Wang A, Nomura M, Patan S, Ware JA. Inhibition of Protein Kinase C α Prevents Endothelial Cell Migration and Vascular Tube Formation In Vitro and Myocardial Neovascularization In Vivo. Circ Res. 2002; 90: 609-616. doi: 10.1161/01.RES.0000012503.30315.E8 PMID: 11909826
73. Vaira V, Faversani A, Dohi T, Maggioni M, Nosotti M, Tosi D, et al. Aberrant Overexpression of the Cell Polarity Module Scribble in Human Cancer. Am J Pathol. 2011; 178: 2478-2483. doi: 10.1016/j.ajpath.2011.02.028 PMID: 21549346
74. George J, Banik NL, Ray SK. Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines. Int J Biochem Cell Biol. 2010; 42: 1164-1173. doi: 10.1016/j.biocel.2010.04.002 PMID: 20394835
75. Renné C, Willenbrock K, Martin-Subero JI, Hinsch N, Döring C, Tiacci E, et al. High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia. 2007; 21: 780-787. doi: 10.1038/sj.leu.2404594 PMID: 17375124
76. Mottok A, Renné C, Willenbrock K, Hansmann M-L, Bräuninger A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood. 2007; 110: 3387-3390. doi: 10.1182/blood-2007-03-082511 PMID: 17652621
77. Park MJ, Park IC, Hur JH, Rhee CH, Choe TB, Yi DH, et al. Protein kinase C activation by phorbol ester increases in vitro invasion through regulation of matrix metalloproteinases/tissue inhibitors of metalloproteinases system in D54 human glioblastoma cells. Neurosci Lett. 2000; 290: 201-204. PMID: 10963898
78. Mizejewski GJ, MacColl R. Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics. Mol Cancer Ther. 2003; 2: 1243-1255. PMID: 14617798
79. Vakharia D, Mizejewski GJ. Human alpha-fetoprotein peptides bind estrogen receptor and estradiol, and suppress breast cancer. Breast Cancer Res Treat. 2000; 63: 41-52. PMID: 11079158
80. Li M-S, Li P-F, Chen Q, Du G-G, Li G. Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. World J Gastroenterol WJG. 2004; 10: 819-824. PMID: 15040024
81. Li M, Li H, Li C, Wang S, Jiang W, Liu Z, et al. Alpha-fetoprotein: a new member of intracellular signal molecules in regulation of the PI3K/AKT signaling in human hepatoma cell lines. Int J Cancer J Int Cancer. 2011; 128: 524-532. doi: 10.1002/ijc.25373 PMID: 20473866
82. Cong Y, Shay JW. Actions of human telomerase beyond telomeres. Cell Res. 2008; 18: 725-732. doi: 10.1038/cr.2008.74 PMID: 18574498
83. Zheng L, Gong W, Liang P, Huang X, You N, Han KQ, et al. Effects of AFP-activated PI3K/Akt signaling pathway on cell proliferation of liver cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014; doi: 10.1007/s13277-013-1535-z
84. Chang JT, Lu Y-C, Chen Y-J, Tseng C-P, Chen Y-L, Fang C-W, et al. hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cells. Br J Cancer. 2006; 94: 870-878. doi: 10.1038/sj.bjc.6603008 PMID: 16508638
85. Butturini E, Cavalieri E, Carcereri de Prati A, Darra E, Rigo A, Shoji K, et al. Two Naturally Occurring Terpenes, Dehydrocostuslactone and Costunolide, Decrease Intracellular GSH Content and Inhibit STAT3 Activation. PLoS ONE. 2011; 6: e20174. doi: 10.1371/journal.pone.0020174 PMID: 21625597